Dr. Marie Roskrow, MBBS Ph.D.

Dr. Roskrow obtained a Bachelor of Science degree (First Class) in Immuno-haematology and a Medical Degree (MBBS with Honours) from the University of London in 1991. She undertook specialized training in Haematology and Oncology and was awarded a Ph.D. (Medicine) by the University of London, following a Fellowship at St Jude Children’s Research Hospital in Memphis. 
Dr. Roskrow moved to the GSF Munich in 1997. Her scientific work focused on the generation of viral-specific T cells for the treatment of patients with lymphoproliferative diseases. She was awarded the “Gerhard Hess Prize” from the German Research Foundation (DFG) for her research. 
In 2000, Dr. Roskrow joined the investment bank Lazard and, for the next years, worked in New York, San Francisco and Sydney specializing in biotechnology mergers and acquisitions. 
In 2010, Dr. Roskrow became Chief Medical Officer for Patrys Ltd, a publicly-traded Australian biotechnology company specializing in the development of novel monoclonal antibodies for the treatment of cancer. In 2011 she was appointed Chief Executive Officer / Managing Director. In 2014, she worked as a freelance business consultant and now serves as the Chief Executive Officer (CEO) at ImevaX.

Volker Wedershoven

Volker Wedershoven holds a degree in Business Administration from the LMU Munich. He started his career as the assistant to the managing director of a company in the machinery business. The company specialized in developing, constructing and servicing dedicated machines for the pharmaceutical industry. 
Volker Wedershoven acquired his first shares in the company in 1992 and was a major shareholder by the time of selling the company. In 1992 he was announced Managing Director. Until 2010 the company went through a successful growth process from 35 employees to 480 employees. He established two daughter companies in the USA and additional sales points in Europe and Asia. The two shareholders in the company accepted an offer to sell in 2010. 
After selling the company, he worked as a consultant and Business Angel in various projects in different industries. Volker Wedershoven now serves as Chief Financial Officer (CFO) at ImevaX.

Dr. Uwe Michaelis

Dr. Uwe Michaelis obtained a Ph.D. from the Institute of Genetics and Microbiology of the Ludwigs-Maximilians Universität (LMU) in Munich. From 1991 to 1998, he held various positions at Boehringer Mannheim GmbH/ROCHE in the area of research and development of biotechnology-based drugs.
In 1998, Dr. Uwe Michaelis co-founded Munich Biotech AG, where he served as CSO. His extensive experience in all phases of company startup was the prerequisites for growing Munich Biotech AG to some 60 employees and taking the development of drug candidates to clinical phase I trials. 
After the takeover of Munich Biotech AG by MediGene AG in 2004, Dr. Uwe Michaelis initially served as Vice President Research before becoming VP Early-Stage Drug Development. While he was the project leader of “Strategic Investments”, the oncological herpes simplex virus (HSV) platform was spun out into the US company Catherex. 
In 2012, he founded his business consultancy, MICHAELIS BIOSCIENCE. Dr. Uwe Michaelis currently advises ImevaX on early-stage drug development and manufacturing issues. As COO he is leading all development activities.